Rituximab for severe aplastic anemia with platelet transfusion problems
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests if the drug rituximab can help people with severe aplastic anemia whose bodies have stopped responding to platelet transfusions. It aims to see if rituximab can improve the body's ability to accept platelets again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been newly diagnosed with severe aplastic anemia and have platelet transfusion refractoriness (meaning your body does not respond well to platelet transfusions).
- You cannot be allergic to rituximab.
- You cannot have a serious active infection, low antibody levels (hypogammaglobulinemia), or severe heart failure.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
This trial tests whether an early bone marrow transplant from a half-matched family member or an unrelated donor can help people with severe aplastic anemia. It aims to restore the body's ability to make healthy blood cells.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial studies using a donor's blood stem cells (from bone marrow or blood) for a transplant in people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if using a mix of both types of cells is better than just blood cells alone.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.